Literature DB >> 18452077

Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.

Floor Pietersma1, Erwan Piriou, Debbie van Baarle.   

Abstract

After infection with the Epstein - Barr virus, a common gammaherpes virus which infects and persists in the B cells, an equilibrium is established in which newly infected and differentiating B cells are controlled by cytotoxic T cell (CTL) responses. Disturbance of this equilibrium, which can occur in immunocompromised situations, can lead to uncontrolled lymphoproliferation and subsequent development of non-Hodgkin Lymphomas (NHL). Here, we review the role of immunesurveillance of EBV-infected B cells and two situations where immunesurveillance is altered because of immunodeficiencies, transplantation recipients and HIV infection, which can lead to EBV-mediated NHL. In transplant recipients, immunosuppression prior and during transplantation can lead to lack of immunesurveillance and results in proliferation of infected B cells, which would normally be controlled by CTL responses. Interestingly, in HIV infection both deregulation of the normal B cell biology and a reduction in immunity play a role in developing NHL. Therefore, the nature of EBV infection in HIV-positive subjects is very different from that in transplanted individuals, in whom (re-)appearance of EBV-specific CD8(+) T cells - either by a decrease in immune suppression or infusion of donor lymphocytes - immediately leads to a decrease in EBV load.

Entities:  

Mesh:

Year:  2008        PMID: 18452077     DOI: 10.1080/10428190801911662

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  25 in total

1.  Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease.

Authors:  Sumathi Sankaran-Walters; Kanat Ransibrahmanakul; Irina Grishina; Jason Hung; Enrique Martinez; Thomas Prindiville; Satya Dandekar
Journal:  J Clin Virol       Date:  2010-10-28       Impact factor: 3.168

2.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

3.  Current status of immunotherapy for the treatment of lung cancer.

Authors:  Sanjay Murala; Vamsi Alli; Daniel Kreisel; Andrew E Gelman; Alexander S Krupnick
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

Review 4.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

Review 5.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

6.  Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.

Authors:  Álvaro H Borges; Jacqueline Neuhaus; Abdel G Babiker; Keith Henry; Mamta K Jain; Adrian Palfreeman; Peter Mugyenyi; Pere Domingo; Christian Hoffmann; Tim R H Read; Sanjay Pujari; Michael Meulbroek; Margaret Johnson; Timothy Wilkin; Ronald Mitsuyasu
Journal:  Clin Infect Dis       Date:  2016-09-08       Impact factor: 9.079

7.  Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Marta Epeldegui; Otoniel Martínez-Maza
Journal:  For Immunopathol Dis Therap       Date:  2015

Review 8.  Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.

Authors:  Jordan E Axelrad; Simon Lichtiger; Vijay Yajnik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

9.  Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota.

Authors:  Siddhant Yadav; Siddharth Singh; W Scott Harmsen; Jithinraj Edakkanambeth Varayil; William J Tremaine; Edward V Loftus
Journal:  Mayo Clin Proc       Date:  2015-05-09       Impact factor: 7.616

Review 10.  Monitoring for Extra-Intestinal Cancers in IBD.

Authors:  H Sifuentes; S Kane
Journal:  Curr Gastroenterol Rep       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.